BE2021C530I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2021C530I2 BE2021C530I2 BE2021C530C BE2021C530C BE2021C530I2 BE 2021C530 I2 BE2021C530 I2 BE 2021C530I2 BE 2021C530 C BE2021C530 C BE 2021C530C BE 2021C530 C BE2021C530 C BE 2021C530C BE 2021C530 I2 BE2021C530 I2 BE 2021C530I2
- Authority
- BE
- Belgium
- Prior art keywords
- group
- component
- aforementioned
- parenteral
- rectal administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01201947 | 2001-05-23 | ||
EP01201946 | 2001-05-23 | ||
EP01201945A EP1293210B1 (en) | 2001-05-23 | 2001-05-23 | Means and method for hormonal contraception |
EP01203305A EP1287817A1 (en) | 2001-08-31 | 2001-08-31 | Method of treating uterine leiomyomas and intravaginal drug delivery vehicle for use in such method |
EP01204377 | 2001-11-15 | ||
EP02738960A EP1390041B1 (en) | 2001-05-23 | 2002-05-23 | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
PCT/NL2002/000330 WO2002094278A1 (en) | 2001-05-23 | 2002-05-23 | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2021C530I2 true BE2021C530I2 (es) | 2021-08-09 |
Family
ID=27513106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2021C530C BE2021C530I2 (es) | 2001-05-23 | 2021-07-29 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7871995B2 (es) |
EP (1) | EP1390041B1 (es) |
AT (1) | ATE449606T1 (es) |
BE (1) | BE2021C530I2 (es) |
CA (1) | CA2448273C (es) |
DE (1) | DE60234515D1 (es) |
ES (1) | ES2337129T3 (es) |
WO (1) | WO2002094278A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004037269A1 (en) | 2002-10-23 | 2004-05-06 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
AU2003279624A1 (en) | 2002-11-08 | 2004-06-07 | Pantarhei Bioscience B.V. | Synthesis of estetrol via estrone derived steroids |
HUP0303313A2 (hu) * | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transzdermális gyógyszerkészítmények |
US20050222106A1 (en) * | 2004-04-01 | 2005-10-06 | Stefan Bracht | Drospirenone-containing preparations for transdermal use |
WO2008019048A1 (en) * | 2006-08-04 | 2008-02-14 | Meditrina Pharmaceuticals | Use of aromatase inhibitors for thining the endometrium or treating menorrhagia |
US8236785B2 (en) * | 2007-01-08 | 2012-08-07 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
ES2378117T3 (es) * | 2007-06-21 | 2012-04-09 | Pantarhei Bioscience B.V. | Tratamiento del Síndrome de aspiración de meconio con estrógenos |
US20100292150A1 (en) * | 2007-12-10 | 2010-11-18 | Meditrina Pharmaceuticals, Inc. | Treatment of Menorrhagia with Aromatase Inhibitor |
US9381193B2 (en) * | 2011-04-01 | 2016-07-05 | Washington University | Contraceptive methods and compositions |
US11053274B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
LT2714712T (lt) | 2011-06-01 | 2016-11-25 | Estetra S.P.R.L. | Estetrolio tarpinių junginių gamybos būdas |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
EA028780B1 (ru) * | 2011-08-11 | 2017-12-29 | Эстетра С.П.Р.Л. | Применение эстетрола в качестве экстренного контрацептива |
WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
WO2015040051A1 (en) | 2013-09-18 | 2015-03-26 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
PL3079671T3 (pl) | 2013-12-12 | 2018-03-30 | Donesta Bioscience B.V. | Rozpadająca się w jamie ustnej stała jednostka dawkowania zawierająca składnik estetrolowy |
US11147771B2 (en) | 2015-06-18 | 2021-10-19 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
PL3310346T3 (pl) * | 2015-06-18 | 2021-10-25 | Estetra Sprl | Dyspergowalna w ustach tabletka zawierająca estetrol |
ES2877186T3 (es) | 2015-06-18 | 2021-11-16 | Estetra Sprl | Comprimido orodispersable que contiene estetrol |
TN2017000499A1 (en) | 2015-06-18 | 2019-04-12 | Mithra Pharmaceuticals S A | Orodispersible dosage unit containing an estetrol component |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
BE1027858B1 (fr) * | 2019-12-13 | 2021-07-14 | Georges Debled | Composition pharmaceutique pour la contraception chez la femme |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3440320A (en) | 1964-06-18 | 1969-04-22 | Mortimer D Sackler | Chelated suppository and method of using same |
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
DE2426779A1 (de) | 1974-05-31 | 1975-12-18 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
DE2336434A1 (de) | 1973-07-13 | 1975-04-17 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
DE2336433A1 (de) | 1973-07-13 | 1975-04-03 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
US4722941A (en) | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
US4460372A (en) | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4573996A (en) | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
US4624665A (en) | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4937238A (en) | 1986-03-04 | 1990-06-26 | The Board Of Regents Of The University Of Nebraska | Prevention of mammary carcinoma |
US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
US5223261A (en) | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
US5043331A (en) | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
US5130137A (en) | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
JPH04235171A (ja) | 1990-07-26 | 1992-08-24 | Sumitomo Chem Co Ltd | スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤 |
US5063507A (en) | 1990-09-14 | 1991-11-05 | Plains Cotton Cooperative Association | Goods database employing electronic title or documentary-type title |
US5211952A (en) | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
US5895783A (en) | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
NL9301562A (nl) | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
WO1996003929A1 (en) | 1994-08-04 | 1996-02-15 | Biex, Inc. | Method for prediction of premature delivery using estetrol (e4) as an indicator |
DE4429374C1 (de) | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
DK0994718T3 (da) | 1997-06-20 | 2005-12-19 | Akzo Nobel Nv | Gonadotropin releasing hormon-antagonist |
DE19739916C2 (de) | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US6214815B1 (en) | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
AU4543200A (en) | 1999-04-16 | 2000-11-02 | Dittgen, Michael | Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones |
AU5137900A (en) | 1999-05-28 | 2000-12-18 | University Of Cincinnati, The | Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use |
WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
DE60129550T2 (de) | 2000-05-12 | 2008-04-10 | The Government Of The United States Of America, As Represented By The Department | Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten |
US6936599B2 (en) | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
-
2002
- 2002-05-23 AT AT02738960T patent/ATE449606T1/de not_active IP Right Cessation
- 2002-05-23 WO PCT/NL2002/000330 patent/WO2002094278A1/en not_active Application Discontinuation
- 2002-05-23 DE DE60234515T patent/DE60234515D1/de not_active Expired - Lifetime
- 2002-05-23 EP EP02738960A patent/EP1390041B1/en not_active Expired - Lifetime
- 2002-05-23 CA CA2448273A patent/CA2448273C/en not_active Expired - Lifetime
- 2002-05-23 ES ES02738960T patent/ES2337129T3/es not_active Expired - Lifetime
- 2002-05-23 US US10/478,357 patent/US7871995B2/en active Active
-
2021
- 2021-07-29 BE BE2021C530C patent/BE2021C530I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US7871995B2 (en) | 2011-01-18 |
CA2448273C (en) | 2010-06-29 |
WO2002094278A1 (en) | 2002-11-28 |
CA2448273A1 (en) | 2002-11-28 |
ATE449606T1 (de) | 2009-12-15 |
EP1390041B1 (en) | 2009-11-25 |
EP1390041A1 (en) | 2004-02-25 |
US20040192620A1 (en) | 2004-09-30 |
DE60234515D1 (de) | 2010-01-07 |
ES2337129T3 (es) | 2010-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE2021C530I2 (es) | ||
WO2002094275A8 (en) | Use of estrogen compounds to increase libido in women | |
DK1446128T3 (da) | Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling | |
DE60217324D1 (de) | Pharmaceutishe zusammensetzung für die hormonersatztherapie | |
MXPA03001072A (es) | El uso de bencilidenaminoguanidinas e hidroxiguanidinas como ligandos de receptor de melanocortina. | |
CY1108093T1 (el) | Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη | |
TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
MD1900B2 (en) | Aerosolic pharmaceutical composition and method of treatment of respiratory affections | |
MXPA01011517A (es) | Nucleosidos de 4'-c-etinil-purina. | |
AU4119696A (en) | Method for depositing a hard protective coating | |
PL1624878T3 (pl) | Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu | |
EP0845985A4 (en) | NON-STEROIDIAN SULFATASE INHIBITOR COMPOUNDS AND METHODS OF USE | |
YU7203A (sh) | Derivati benzimidazola, njihovo dobijanje i terapeutska primena | |
CA2217771A1 (en) | O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same | |
AU4246501A (en) | 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity | |
MY128709A (en) | Phosphonites | |
AU2003274946A1 (en) | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein | |
GB8328073D0 (en) | Chemical compounds | |
WO2004006936A8 (en) | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy | |
GB9206768D0 (en) | New compounds for use in the treatment of cancer | |
WO2000061549A3 (en) | Pharmaceutical compounds | |
TW348176B (en) | New compounds with analgestic and local anaesthetic effect | |
TW338063B (en) | Fluorine-containing optically active compound, process for preparing the same and liquid crystal mixture and liquid crystal element comprising the same | |
ZA943241B (en) | Therapeutic agents | |
CA2395481A1 (en) | Hormone receptor modulation |